SUNPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.0
| Stock Code | SUNPHARMA | Market Cap | 4,33,872 Cr. | Current Price | 1,808 ₹ | High / Low | 1,851 ₹ |
| Stock P/E | 99.4 | Book Value | 99.2 ₹ | Dividend Yield | 0.88 % | ROCE | 16.8 % |
| ROE | 17.8 % | Face Value | 1.00 ₹ | DMA 50 | 1,724 ₹ | DMA 200 | 1,713 ₹ |
| Chg in FII Hold | -0.18 % | Chg in DII Hold | 0.28 % | PAT Qtr | 872 Cr. | PAT Prev Qtr | 564 Cr. |
| RSI | 63.0 | MACD | 2.98 | Volume | 49,60,661 | Avg Vol 1Wk | 1,49,37,644 |
| Low price | 1,547 ₹ | High price | 1,851 ₹ | PEG Ratio | 1.36 | Debt to equity | 0.56 |
| 52w Index | 85.9 % | Qtr Profit Var | -24.6 % | EPS | 16.7 ₹ | Industry PE | 30.1 |
📈 Optimal Buy Price: 1,790–1,805 ₹ (near DMA50 support zone)
💰 Profit Exit Levels: 1,835–1,850 ₹ (short-term resistance, close to 52w high)
🛑 Stop-Loss: Below 1,775 ₹ (protect downside risk)
🔄 Intraday Exit Guidance: If RSI (63.0) fails to sustain above 60 or price action struggles near 1,835 ₹ with declining volume, consider booking profits. Exit intraday if volume remains below average despite MACD staying positive.
Positive
- Strong ROE (17.8%) and ROCE (16.8%) indicate efficient capital use
- PEG ratio at 1.36 suggests moderate valuation relative to growth
- Trading well above DMA200 (1,713 ₹), confirming long-term strength
- DII holdings increased (+0.28%), showing domestic institutional confidence
Limitation
- Extremely high P/E (99.4) compared to industry average (30.1)
- Sequential PAT decline (-24.6%) raises earnings concerns
- FII holdings decreased (-0.18%), showing reduced foreign investor confidence
- Volume below weekly average, indicating weaker participation
Company Negative News
- Sharp decline in quarterly profits (872 Cr. vs 564 Cr. previously)
- High valuation multiples may limit upside if growth slows
Company Positive News
- Strong long-term profitability metrics (ROE and ROCE)
- DII stake increased, reflecting domestic institutional support
Industry
- Pharma sector PE at 30.1, much lower than Sun Pharma’s valuation
- Industry supported by global healthcare demand and specialty drug growth
Conclusion
📌 SUNPHARMA is a fundamentally strong company but not ideal for aggressive intraday trading today due to weak volume and stretched valuations. Best entry lies between 1,790–1,805 ₹ with exits near 1,835–1,850 ₹. Intraday traders should maintain strict stop-loss discipline at 1,775 ₹ and monitor RSI and volume closely.
Would you like me to also prepare a sector overlay comparison (Sun Pharma vs Dr. Reddy’s, Cipla, Divi’s Lab) so you can benchmark intraday strength across peers?